Preventing tuberculosis in the foreign-born population of Canada: A mathematical modelling study

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 4, 2014, Pages 405-412

  Varughese, M B ^a   Langlois Klassen, D ^b   Long, Richard ^a,c   Li, M ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Alberta Innovates Bio Solutions   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Latent tuberculous infection; Modelling TB prevention; TB prevention

Indexed keywords

ISONIAZID; TUBERCULOSTATIC AGENT;

AGE DISTRIBUTION; ARTICLE; CANADA; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EPIDEMIOLOGICAL DATA; FACTUAL DATABASE; HEALTH CARE PLANNING; HUMAN; IMMIGRANT; IMMIGRATION; INCIDENCE; INFECTION PREVENTION; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MATHEMATICAL MODEL; POST HOC ANALYSIS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SCREENING TEST; SIMULATION; TUBERCULIN TEST; TUBERCULOSIS CONTROL; VALIDATION PROCESS; ADULT; COMPUTER SIMULATION; DEMOGRAPHY; EPIDEMIOLOGY; ETHNOLOGY; INFECTION CONTROL; MASS SCREENING; MICROBIOLOGY; MIGRANT; MIGRATION; MYCOBACTERIUM TUBERCULOSIS; PATHOGENICITY; PREDICTIVE VALUE; PROCEDURES; PUBLIC HEALTH; RISK FACTOR; THEORETICAL MODEL; TRANSMISSION; VIRUS ACTIVATION;

ADULT; ANTITUBERCULAR AGENTS; CANADA; COMMUNICABLE DISEASE CONTROL; COMPUTER SIMULATION; EMIGRANTS AND IMMIGRANTS; EMIGRATION AND IMMIGRATION; HUMANS; INCIDENCE; LATENT TUBERCULOSIS; MASS SCREENING; MODELS, THEORETICAL; MYCOBACTERIUM TUBERCULOSIS; NATIONAL HEALTH PROGRAMS; PREDICTIVE VALUE OF TESTS; RESIDENCE CHARACTERISTICS; RISK FACTORS; VIRUS ACTIVATION;

EID: 84897148483     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0625     Document Type: Article

References (33)

1. Statistics Canada. 2011 National household survey: immigration, place of birth, citizenship, ethnic origin, visible minorities, language and religion, 2013. Ottawa, ON, Canada: Statistics Canada, 2013. http://www.statcan.gc.ca/ daily-quotidien/130508/dq130508b-eng.pdf Accessed January 2014.
2. Public Health Agency of Canada. Tuberculosis in Canada 2011 pre-release. Ottawa, ON, Canada: Minister of Public Works and Government Services Canada, 2012.
3. Kunimoto D, Sutherland K, Wooldrage K, et al. Transmission characteristics of tuberculosis in the foreign-born and the Canadian-born populations of Alberta, Canada. Int J Tuberc Lung Dis 2004; 8: 1213-1220. (Pubitemid 39371834)
4. Ricks P M, Cain K P, Oeltmann J E, Krammerer J S, Moonan P K. Estimating the burden of tuberculosis among foreign-born persons acquired prior to entering the US, 2005-2009. PLOS ONE 2011; 6: e27405.
5. Jensen M, Lau A, Langlois-Klassen D, Boffa J, Manfreda J, Long R. A population-based study of tuberculosis epidemiology and innovative service delivery in Canada. Int J Tuberc Lung Dis 2012; 16: 43-49.
6. Linas B P, Wong AY, Freedberg K A, HorsburghC R Jr. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011; 5: 590-601.
7. Horsburgh C R Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 20: 2060-2067.
8. Langlois-Klassen D, Wooldrage KM, Manfreda J, et al. Piecing the puzzle together: foreign-born tuberculosis in an immigrant-receiving country. Eur Respir J 2011; 38: 895-902.
9. Smieja MJ, Marchetti C A, Cook D J, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV-infected persons. Cochrane Database Syst Rev 2000; 2: CD001363.
10. Ziakas P D, Mylonakis E. 4 Months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis 2009; 12: 1883-1889.
11. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184.
12. Statistics Canada. CANSIM: Table 102-0504. Death and mortality rates, by age group and sex, Canada, provinces and territories annual. Ottawa, ON, Canada: Statistics Canada, 2009. http://www5.statcan.gc.ca/cansim/a26?lang=eng& retrLang=eng&id=1020504&paSer=&pattern=&stByVal =1&p1=1&p2=-1&tabMode=dataTable&csid= Accessed January 2014.
13. Nguyen D, Menzies D. Diagnosis and treatment of latent TB infection. CJEM 2001; May: 89-97.
14. Ellis E, Deeks S, Phypers M, Medaglia A, Sheardown C. Tuberculosis in Canada 2000: tuberculosis among the foreign born in Canada. Ottawa, ON, Canada: Minister of Public Works and Government Services, 2003.
15. Menzies D, Chan C H, Vissandjee B. Impact of immigration on tuberculosis infection among Canadian-born school children and young adults in Montreal. Am J Respir Crit Care Med 1997; 156: 1915-1921. (Pubitemid 28011802)
16. Cain K P, Benoit S R, Winston C A, et al. Tuberculosis among foreign-born persons in the United States. JAMA 2008; 300: 405-412. (Pubitemid 352040252)
17. Greenaway C, Sandoe A, Vissandjee B, et al. Tuberculosis: evidence review for newly arriving immigrants and refugees. CMAJ 2010; 183: E939-E951.
18. th ed. Ottawa, ON, Canada: Public Health Agency of Canada, 2007: pp 1-438;
19. Morrison J, Pai M, Hopewell P C. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8: 359-368.
20. Oxlade O, Schwarzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007; 11: 16-26. (Pubitemid 46101841)
21. Jacobs S, Warman A, Richardson R, et al. The tuberculin skin test is unreliable in school children BCG-vaccinated in infancy and at low risk of tuberculosis infection. Pediatr Infect Dis J 2011; 30: 754-758.
22. Wang L, TurnerMO, Elwood R K, Schulzer M, FitzGerald JM. A meta-analysis of the effect of bacille Calmette-Guerin vaccination on tuberculosis skin test measurements. Thorax 2002; 57: 804-809. (Pubitemid 34984980)
23. Gantz NM, Brown R B, Berk S L, Esposito A L, Gleckman R A. Manual of clinical problems in infectious disease. 5th ed. Philadelphia, PA, USA: Lippincott Williams and Wilkins, 2006: pp 1-576.
24. Centers for Disease Control and Prevention. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 2011; 60: 1650-1653.
25. Ziv E, Daley C L, Blower S M. Early therapy for latent tuberculosis infection. Am J Epidemiol 2002; 153: 381-385.
26. Tan MC, Marra C A, Sadatasfavi M, et al. Cost-effectiveness of LTBI treatment for TB contacts in British Columbia. Value Health 2008; 11: 842-852.
27. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. A cost-effectiveness analysis. Am J Respir Crit Care Med 2000; 161: 780-789. (Pubitemid 30171731)
28. Menzies D, Dion M J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170: 445-449. (Pubitemid 39214621)
29. Sterling T R, Villarino ME, Borisov A S, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-2166.
30. Al-Orainey I O. Diagnosis of latent tuberculosis: can we do better? Ann Thorac Med 2009; 4: 5-9.
31. Health Canada. National tuberculosis elimination strategy. Ottawa, ON, Canada: Health Canada, 2010. http://www.hc-sc.gc.ca/fniah-spnia/diseases- maladies/tuberculos /intro-eng.php Accessed January 2014.
32. Stop TB Partnership, World Health Organization. The Global Plan to Stop TB 2006-2015. WHO/HTM/STB/2006.35. Geneva, Switzerland: WHO, 2006. http://www.who.int/tb/publications/global-plan-to-stop-tb/en/ Accessed January 2014.
33. Dasgupta K, Menzies D. Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J 2005; 25: 1107-1116. (Pubitemid 40823787)